DK3028716T3 - Komplementhæmning til forbedret nerveregeneration - Google Patents

Komplementhæmning til forbedret nerveregeneration Download PDF

Info

Publication number
DK3028716T3
DK3028716T3 DK15187453.4T DK15187453T DK3028716T3 DK 3028716 T3 DK3028716 T3 DK 3028716T3 DK 15187453 T DK15187453 T DK 15187453T DK 3028716 T3 DK3028716 T3 DK 3028716T3
Authority
DK
Denmark
Prior art keywords
generation
complementary inhibition
nervous
improved nervous
improved
Prior art date
Application number
DK15187453.4T
Other languages
English (en)
Inventor
Frank Baas
Valeria Ramaglia
Original Assignee
Regenesance B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38857887&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3028716(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regenesance B V filed Critical Regenesance B V
Application granted granted Critical
Publication of DK3028716T3 publication Critical patent/DK3028716T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK15187453.4T 2006-10-10 2007-10-10 Komplementhæmning til forbedret nerveregeneration DK3028716T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85027706P 2006-10-10 2006-10-10
EP13181901.3A EP2698166B1 (en) 2006-10-10 2007-10-10 Complement inhibition for improved nerve regeneration

Publications (1)

Publication Number Publication Date
DK3028716T3 true DK3028716T3 (da) 2020-11-23

Family

ID=38857887

Family Applications (2)

Application Number Title Priority Date Filing Date
DK15187453.4T DK3028716T3 (da) 2006-10-10 2007-10-10 Komplementhæmning til forbedret nerveregeneration
DK13181901.3T DK2698166T3 (da) 2006-10-10 2007-10-10 Komplementærhæmning for bedre nerveregeneration

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK13181901.3T DK2698166T3 (da) 2006-10-10 2007-10-10 Komplementærhæmning for bedre nerveregeneration

Country Status (16)

Country Link
US (4) US8703136B2 (da)
EP (4) EP3804755A1 (da)
JP (2) JP2010505946A (da)
AU (1) AU2007307375B2 (da)
CA (3) CA3154415A1 (da)
CY (1) CY1123734T1 (da)
DK (2) DK3028716T3 (da)
ES (2) ES2831325T3 (da)
HK (2) HK1194688A1 (da)
HU (2) HUE026042T2 (da)
LT (1) LT3028716T (da)
NZ (1) NZ576195A (da)
PL (2) PL2698166T3 (da)
PT (2) PT3028716T (da)
SI (2) SI3028716T1 (da)
WO (1) WO2008044928A1 (da)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ576195A (en) 2006-10-10 2012-04-27 Az Univ Amsterdam Complement inhibition for improved nerve regeneration
AU2014200822B2 (en) * 2006-10-10 2016-01-28 Regenesance B.V. Complement inhibition for improved nerve regeneration
NZ591057A (en) * 2008-07-10 2012-11-30 Az Univ Amsterdam Complement antagonists and uses thereof
WO2010022149A1 (en) * 2008-08-20 2010-02-25 The Trustees Of The University Of Pennsylvania Complement inhibitors for treatment of injury form intracerebral hemorrhage
WO2011105902A2 (en) 2010-02-23 2011-09-01 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Antagonists of complement component 8-beta (c8-beta) and uses thereof
WO2011105901A2 (en) 2010-02-23 2011-09-01 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Antagonists of complement component 9 (c9) and uses thereof
WO2011105900A2 (en) 2010-02-23 2011-09-01 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Antagonists of complement component 8-alpha (c8-alpha) and uses thereof
JP6253578B2 (ja) 2011-07-22 2017-12-27 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 阻害性抗第ｘｉｉ／ｘｉｉａ因子モノクローナル抗体及びそれらの使用
EP2623110A1 (en) * 2012-01-31 2013-08-07 CSL Behring GmbH Factor XII inhibitors for the treatment of neurological inflammatory disorders
WO2014066744A2 (en) 2012-10-25 2014-05-01 True North Therapeutics, Inc. Anti-complement c1s antibodies and uses thereof
US8945562B2 (en) 2012-11-02 2015-02-03 True North Therapeutics, Inc. Anti-complement C1s antibodies
AU2014224599B2 (en) 2013-03-08 2018-11-08 Csl Behring Gmbh Treatment and prevention of remote ischemia-reperfusion injury
DK3154561T3 (da) 2014-06-12 2019-10-07 Ra Pharmaceuticals Inc Modulering af komplementaktivitet
KR20230137502A (ko) * 2014-12-19 2023-10-04 레제네상스 비.브이. 인간 c6에 결합하는 항체 및 이의 용도
LT3250230T (lt) 2015-01-28 2021-12-27 Ra Pharmaceuticals, Inc. Komplemento aktyvumo moduliatoriai
LT3280440T (lt) 2015-04-06 2023-02-27 Bioverativ Usa Inc. Humanizuoti antikūnai prieš c1s ir jų panaudojimo būdai
SG11201804721SA (en) 2015-12-16 2018-07-30 Ra Pharmaceuticals Inc Modulators of complement activity
EP3405577B8 (en) 2016-01-20 2023-02-15 396419 B.C. Ltd. Compositions and methods for inhibiting factor d
MA45235A (fr) 2016-06-14 2019-04-17 Regeneron Pharma Anticorps anti-c5 et leurs utilisations
JP7301741B2 (ja) 2016-12-07 2023-07-03 ラ ファーマシューティカルズ インコーポレイテッド 補体活性のモジュレータ
WO2018136827A1 (en) 2017-01-20 2018-07-26 Vitrisa Therapeutics, Inc. Stem-loop compositions and methods for inhibiting factor d
JP2021505565A (ja) 2017-12-04 2021-02-18 ラ ファーマシューティカルズ インコーポレイテッドＲａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 補体活性のモジュレータ
EP3724226A1 (en) 2017-12-13 2020-10-21 Regeneron Pharmaceuticals, Inc. Anti-c5 antibody combinations and uses thereof
US11161900B2 (en) 2018-12-13 2021-11-02 Argenx Bvba Antibodies that specifically bind to human complement factor C2b
TW202100179A (zh) 2019-03-08 2021-01-01 美商Ｒａ製藥公司 補體活性之調節劑
WO2020205501A1 (en) 2019-03-29 2020-10-08 Ra Pharmaceuticals, Inc. Complement modulators and related methods
JP2022530042A (ja) 2019-04-24 2022-06-27 ラ ファーマシューティカルズ インコーポレイテッド 補体活性を調節するための組成物及び方法
GB2584105B (en) * 2019-05-21 2023-08-02 Argenx Bvba Methods of treating neuropathy
CN115605592A (zh) 2020-05-11 2023-01-13 基因泰克公司（Us） 用于治疗神经系统疾病的补体组分c1r抑制剂以及相关的组合物、系统和使用它们的方法
WO2021231204A1 (en) 2020-05-11 2021-11-18 Genentech, Inc. Complement component 4 inhibitors for treating neurological diseases, and related compositons, systems and methods of using same
WO2021231211A1 (en) 2020-05-11 2021-11-18 Genentech, Inc. Complement component c1s inhibitors for treating a neurological disease, and related compositions, systems and methods of using same
WO2024081954A2 (en) 2022-10-14 2024-04-18 Sanegene Bio Usa Inc. Small interfering rna targeting c3 and uses thereof
WO2024137590A2 (en) 2022-12-19 2024-06-27 Sanegene Bio Usa Inc. Small interfering rna targeting cfb and uses thereof

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
IL89790A (en) 1988-04-01 2002-05-23 Johns Hopking University Sequences of nucleic acids encoding and cells producing CR1 protein and methods for its production and purification
US5256642A (en) 1988-04-01 1993-10-26 The Johns Hopkins University Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5177190A (en) 1989-01-03 1993-01-05 Merck & Co., Inc. Purified C5a receptor from human polymorphonuclear leukocytes
JPH05503001A (ja) 1989-10-27 1993-05-27 スティッチング　セントラール　ラボラトリウム　ファン　デ　ブルートトランスフュジエディエンスト　ファン　ヘット　ネデールランツェ　ローデ　クルイス Ｃ１インヒビターミューティンおよびその利用
GB9007971D0 (en) 1990-04-09 1990-06-06 Imutran Ltd Pharmaceutical formulations
WO1992022320A1 (en) 1991-06-14 1992-12-23 Genentech, Inc. C1 inhibitor variants and treating inflammatory response with c1 inhibitor
DE4222534A1 (de) * 1992-07-09 1994-01-13 Behringwerke Ag Verwendung von Komplement-Inhibitoren zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie von entzündlichen Darm- und Hauterkrankungen sowie Purpura
EP1621554B2 (en) 1992-08-21 2012-08-29 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
DE4227762A1 (de) 1992-08-24 1994-03-03 Behringwerke Ag Verwendung eines Kallikrein-Inhibitors zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie bestimmter Krankheiten
US6838254B1 (en) 1993-04-29 2005-01-04 Conopco, Inc. Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae
US5480974A (en) 1993-06-18 1996-01-02 The Scripps Research Institute Antibodies to human C5a receptor
FR2708622B1 (fr) 1993-08-02 1997-04-18 Raymond Hamers Vecteur recombinant contenant une séquence d'un gène de lipoprotéine de structure pour l'expression de séquences de nucléotides.
ES2171465T3 (es) 1993-09-01 2002-09-16 Sanquin Bloedvoorziening Inhibidor de la esterasa de c1 para reducir lesiones de miocardio durante un infarto de miocardio agudo.
US5627264A (en) 1994-03-03 1997-05-06 Alexion Pharmaceuticals, Inc. Chimeric complement inhibitor proteins
JPH09510088A (ja) 1994-03-03 1997-10-14 アレクション・ファーマシューティカル・インク 最終補体インヒビター融合遺伝子およびタンパク質
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5679345A (en) * 1994-06-02 1997-10-21 The Johns Hopkins University Method for preventing complement-dependent rejection of organ or tissue transplants
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
US6267955B1 (en) 1995-09-15 2001-07-31 Yeda Research And Development Co. Ltd. Mononuclear phagocytes and their use to promote axonal regeneration
SE9503495L (sv) 1995-10-09 1997-04-10 Actinova Ltd Nytt protein
US5843884A (en) 1995-11-15 1998-12-01 Oklahoma Medical Research Foundation C9 complement inhibitor
US5922690A (en) 1996-04-25 1999-07-13 Van Gorp; Cornelius L. Dermatan disulfate, an inhibitor of thrombin generation and activation
EP0937140B1 (en) 1996-06-27 2007-09-26 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Antibody molecules which interact specifically with the active site or cleft of a target molecule
DE69833755T2 (de) 1997-05-21 2006-12-28 Biovation Ltd. Verfahren zur herstellung von nicht-immunogenen proteinen
JP2001513576A (ja) 1997-08-26 2001-09-04 グリアテック インコーポレイテッド 側副経路を介する補体活性化を阻害するためのプロセス
AU748143B2 (en) 1997-10-28 2002-05-30 University Of British Columbia, The Immunological compositions and methods of use to transiently alter mammalian central nervous system myelin to promote neuronal regeneration
EP1051493A2 (en) 1998-01-26 2000-11-15 Unilever Plc Method for producing antibody fragments
WO1999037149A1 (en) 1998-01-27 1999-07-29 Brigham & Women's Hospital Methods of treating cytotoxic damage
AU3066699A (en) 1998-03-03 1999-09-20 Johns Hopkins University, The Smallpox inhibitor of complement enzymes (spice) protein and methods of inhibiting complement activation
US20030096775A1 (en) 2001-10-23 2003-05-22 Isis Pharmaceuticals Inc. Antisense modulation of complement component C3 expression
WO2000029033A2 (en) * 1998-11-17 2000-05-25 The General Hospital Corporation A method of genetic vector delivery
CA2347734A1 (en) 1998-12-15 2000-06-22 Brigham And Women's Hospital, Inc. Methods and products for regulating lectin complement pathway associated complement activation
BR9916765A (pt) 1999-01-05 2001-09-25 Unilever Nv Processo para produzir um material imunoadsorvente, uso de uma proteìna que é ligada por meio de uma ligação covalente a um fragmento de anticorpo, material imunadsorvente, uso de um material, e, kit de teste diagnóstico
AU2291700A (en) 1999-01-19 2000-08-07 Unilever Plc Method for producing antibody fragments
EP1152759A2 (en) 1999-02-09 2001-11-14 3-Dimensional Pharmaceuticals, Inc. METHODS OF TREATING C1s-MEDIATED DISEASES AND CONDITIONS, AND COMPOUNDS AND COMPOSITIONS THEREFOR
BR0009866A (pt) 1999-04-22 2002-01-08 Unilever Nv Método de inibição de infecção viral, uso de uma proteìna de ligação de antìgeno monovalente, produto alimentìcio, composição farmacêutica ou cosmética, proteìna de ligação de antìgeno monovalente, sequência de nucleotìdeos, vetor de expressão, célula hospedeira, e, métodos de seleção e de indentificação de uma proteìna de ligação de antìgeno
JP2002542299A (ja) 1999-04-28 2002-12-10 ユニバーシティ・オブ・ブリティッシュ・コロンビア ミエリン特異性抗体および補体タンパク質を含むニューロン再生用組成物
US6479280B1 (en) 1999-09-24 2002-11-12 Vlaams Interuniversitair Institutuut Voor Biotechnologie Vzw Recombinant phages capable of entering host cells via specific interaction with an artificial receptor
DE60042789D1 (de) 1999-11-29 2009-10-01 Bac Ip B V Immobilisierte antigenbindende moleküle aus einer domäne
DK1242460T3 (da) 1999-11-29 2006-12-11 Unilever Nv Immobilisering af proteiner ved hjælp af et polypeptidsegment
DE60132169T2 (de) 2000-01-31 2008-12-11 Pharming Intellectual Property Bv Humaner c1 inhibitor hergestellt in der milch transgener säugetiere
DE60138333D1 (de) 2000-03-14 2009-05-28 Unilever Nv Variabele Domänen der schweren Kette eines Antikörpers gegen menschliche Ernährungslipasen und deren Verwendungen
AU2001268855A1 (en) 2000-05-26 2001-12-03 National Research Council Of Canada Single-domain antigen-binding antibody fragments derived from llama antibodies
ES2368623T3 (es) 2000-12-13 2011-11-18 Bac Ip B.V. Matrices de proteína de dominios variables de inmunoglobulina de cadena pesada de camilidae.
DE10112617A1 (de) * 2001-03-14 2002-10-02 Aventis Behring Gmbh Verwendung eines C1-Esterase-Inhibitors zur Verhinderung oder Verzögerung der Abstoßung von Xenotransplantaten in Säugetieren
CA2454562A1 (en) * 2001-07-26 2003-02-06 Alexion Pharmaceuticals, Inc. Method of improving cognitive function
EP1433793A4 (en) 2001-09-13 2006-01-25 Inst Antibodies Co Ltd METHOD FOR CREATING A CAMEL ANTIBODY LIBRARY
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
US20050214857A1 (en) 2001-12-11 2005-09-29 Algonomics N.V. Method for displaying loops from immunoglobulin domains in different contexts
EP1456237A2 (en) 2001-12-21 2004-09-15 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Method for cloning of variable domain sequences
EP1461085A2 (en) 2002-01-03 2004-09-29 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Immunoconjugates useful for treatment of tumours
EP1558645B1 (en) 2002-11-08 2011-07-27 Ablynx N.V. Stabilized single domain antibodies in pharmaceutical composition adapted for inhalation
CA2505326A1 (en) 2002-11-08 2004-05-21 Ablynx N.V. Camelidae antibodies against immunoglobulin e and use thereof for the treatment of allergic disorders
ES2392511T3 (es) 2002-11-15 2012-12-11 Musc Foundation For Research Development Moduladores de complemento dianas sobre el receptor 2 de complemento
MXPA05006043A (es) 2003-01-10 2006-01-30 Ablynx Nv Polipeptidos terapeuticos, homologos de los mismos, fragmentos de los mismos y para uso al modular la agregacion mediada de plaquetas.
AU2004216176B2 (en) 2003-02-21 2008-04-03 Genentech, Inc. Methods for preventing and treating tissue damage associated with ischemia-reperfusion injury
PL1626736T3 (pl) * 2003-05-16 2021-05-04 Pharming Intellectual Property B.V. Inhibitor c1 o krótkim okresie półtrwania do leczenia przejściowego
US7482376B2 (en) 2003-07-03 2009-01-27 3-Dimensional Pharmaceuticals, Inc. Conjugated complement cascade inhibitors
WO2005016285A2 (en) * 2003-08-13 2005-02-24 New York University Compositions and methods for inhibiting slit protein and glypican interactions
US20060233776A1 (en) * 2003-08-19 2006-10-19 Norbert Heimburger C1-inh as a drug for treating viruses pathogenic to humans
US7923010B2 (en) 2003-09-11 2011-04-12 The Board Of Regents Of The University Of Texas System Methods and materials for treating autoimmune diseases and conditions
US20050169921A1 (en) 2004-02-03 2005-08-04 Leonard Bell Method of treating hemolytic disease
US20070116710A1 (en) 2004-02-03 2007-05-24 Leonard Bell Methods of treating hemolytic anemia
EP2340850A1 (en) 2004-02-10 2011-07-06 The Regents of the University of Colorado, a Body Corporate Inhibition of factor B, the alternative complement pathway and methods related thereto
CN1997384A (zh) 2004-03-26 2007-07-11 普罗米克斯有限公司 使用补体C5a受体调节剂治疗神经系统病症
SI1755674T1 (sl) 2004-05-14 2015-04-30 Alexion Pharmaceuticals, Inc. Podaljšanje preživetja alotransplantata z inhibiranjem aktivnosti komplementa
EP1674580A1 (en) * 2004-12-23 2006-06-28 F. Hoffmann-La Roche Ag Method for identifying activators and/or inhibitors of enzyme activity
WO2006103118A2 (en) 2005-04-01 2006-10-05 Umc Utrecht Holding B.V. Therapeutic use of scin, a staphylococcal complement inhibitor in inflammatory diseases
AU2006249835B2 (en) * 2005-05-26 2011-09-08 Musc Foundation For Research Development Inhibition of the alternative complement pathway for treatment of traumatic brain injury, spinal cord injury and related conditions
CA2654440C (en) 2005-06-06 2013-09-03 Girish J. Kotwal Methods for treatment or prophylaxis of atherosclerosis and reperfusion injury
EP1738763A1 (en) * 2005-06-30 2007-01-03 AVANT Immunotherapeutics, Inc. Use of complement inhibitory proteins to treat spinal cord injury
JP2007008876A (ja) * 2005-06-30 2007-01-18 Avant Immunotherapeutics Inc 脊髄損傷を治療するための補体阻害タンパク質の使用
US20070004625A1 (en) * 2005-06-30 2007-01-04 Li Liang-Man Use of complement inhibitory proteins to treat spinal cord injury
AU2005227420B2 (en) 2005-10-14 2013-05-09 Alltech, Inc. Method and compositions for altering cell function
WO2007047995A2 (en) 2005-10-21 2007-04-26 Catalyst Biosciences, Inc. Modified proteases that inhibit complement activation
WO2007056227A2 (en) 2005-11-04 2007-05-18 Genentech, Inc. Use of complement pathway inhibitors to treat ocular diseases
ATE516043T1 (de) * 2005-12-21 2011-07-15 Pharming Intellectual Pty Bv Verwendung von c1-inhibitor zur prävention von ischämischen reperfusionsschäden
MX2008011054A (es) 2006-03-02 2009-03-03 Alexion Pharma Inc Prolongacion de supervivencia de un aloinjerto, mediante la inhibicion de actividad de complemento.
US8241843B2 (en) 2006-06-15 2012-08-14 Eastern Virginia Medical School Methods for regulating complement cascade proteins using astrovirus coat protein and derivatives thereof
GB0617734D0 (en) * 2006-09-08 2006-10-18 Evolutec Ltd Method of treating peripheral nerve disorders
NZ576195A (en) 2006-10-10 2012-04-27 Az Univ Amsterdam Complement inhibition for improved nerve regeneration
US8580735B2 (en) 2007-02-05 2013-11-12 Apellis Pharmaceuticals, Inc. Local complement inhibition for treatment of complement-mediated disorders
JP2010521194A (ja) 2007-03-22 2010-06-24 ノバルティス アーゲー Ｃ５抗原およびその使用
US8192742B2 (en) 2007-03-23 2012-06-05 NovelMed Therapeutics Method of inhibiting complement activation with human anti-factor C3 antibodies and use thereof
US20110008343A1 (en) 2007-06-08 2011-01-13 Lambris John D Method Of Reducing Tissue Loss In Pancreatic Islet Cell Transplantation
WO2009015087A2 (en) 2007-07-20 2009-01-29 Potentia Pharmaceuticals, Inc. Compositions and methods for treatment of trauma
WO2009014633A1 (en) 2007-07-20 2009-01-29 Trustees Of The University Of Pennsylvania Method of treating acute respiratory distress syndrome
JP5697027B2 (ja) 2008-02-15 2015-04-08 タフツ ユニバーシティー マウス網膜上への細胞膜傷害複合体（ｍａｃ）生成のヒト化モデル、並びに、黄斑変性の処置のための組成物とキットと方法
US10632170B2 (en) 2008-02-19 2020-04-28 The Trustees Of The University Of Pennsylvania Administration of compstatin to an individual for the treatment of a tumor
WO2009108153A1 (en) 2008-02-29 2009-09-03 The Brigham And Women's Hospital, Inc. Methods and compositions for the regulation of lectin complement pathway (lcp)- associated complement activation in hyperglycemic myocardial damage
WO2009121065A2 (en) 2008-03-28 2009-10-01 Apellis Ag Modulation and repletion/enhancement of the complement system for treatment of trauma
US20090324585A1 (en) 2008-06-12 2009-12-31 The Trustees of the Leland Standford Junior University Complement inhibitory agents as therapeutics in posttraumatic and degenerative arthritis
WO2010022149A1 (en) 2008-08-20 2010-02-25 The Trustees Of The University Of Pennsylvania Complement inhibitors for treatment of injury form intracerebral hemorrhage
DE102008049136B4 (de) 2008-09-26 2012-10-25 Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie e.V. Neue Regulatoren des angeborenen Immunsystems
CA2738930C (en) 2008-09-30 2021-08-17 The Trustees Of The University Of Pennsylvania Method of inhibiting biomaterial-induced procoagulant activity using complement inhibitors
DK2894165T3 (da) 2008-11-10 2023-03-20 Alexion Pharma Inc Fremgangsmåder og sammensætninger til behandling af komplementforbundne forstyrrelser
WO2010057084A1 (en) 2008-11-14 2010-05-20 Novelmed Therapeutics, Inc. Method of treating ischemia reperfusion injury
GB0906779D0 (en) 2009-04-20 2009-06-03 Natural Environment Res Council Composition
JP5852021B2 (ja) 2010-03-01 2016-02-03 アレクシオン ファーマシューティカルズ， インコーポレイテッド ドゴー病を処置するための方法および組成物
WO2011107591A1 (en) 2010-03-05 2011-09-09 Rigshospitalet Chimeric inhibitor molecules of complement activation
US20130324482A1 (en) 2010-07-09 2013-12-05 Apellis Pharmaceuticals, Inc. Compstatin analogs for treatment of rhinosinusitis and nasal polyposis

Also Published As

Publication number Publication date
US8703136B2 (en) 2014-04-22
CA3154415A1 (en) 2008-04-17
US20100143344A1 (en) 2010-06-10
CA2666466A1 (en) 2008-04-17
HUE052964T2 (hu) 2021-06-28
JP2013189470A (ja) 2013-09-26
EP2698166A2 (en) 2014-02-19
PL2698166T3 (pl) 2016-03-31
EP2073898A1 (en) 2009-07-01
CA2666466C (en) 2017-11-14
SI3028716T1 (sl) 2021-01-29
HUE026042T2 (en) 2016-05-30
HK1225620A1 (zh) 2017-09-15
AU2007307375B2 (en) 2013-11-28
US20180022824A1 (en) 2018-01-25
EP3028716A1 (en) 2016-06-08
CY1123734T1 (el) 2022-03-24
DK2698166T3 (da) 2015-12-21
US20140255395A1 (en) 2014-09-11
NZ576195A (en) 2012-04-27
EP3804755A1 (en) 2021-04-14
PL3028716T3 (pl) 2021-03-08
WO2008044928A1 (en) 2008-04-17
EP3028716B1 (en) 2020-09-16
JP2010505946A (ja) 2010-02-25
HK1194688A1 (zh) 2014-10-24
ES2831325T3 (es) 2021-06-08
AU2007307375A1 (en) 2008-04-17
PT2698166E (pt) 2016-01-27
SI2698166T1 (sl) 2016-02-29
EP2698166A3 (en) 2014-04-02
CA2980614A1 (en) 2008-04-17
EP2698166B1 (en) 2015-09-30
US20220227884A1 (en) 2022-07-21
ES2557056T3 (es) 2016-01-21
LT3028716T (lt) 2020-12-10
PT3028716T (pt) 2020-11-23

Similar Documents

Publication Publication Date Title
DK3028716T3 (da) Komplementhæmning til forbedret nerveregeneration
LTPA2020501I1 (lt) Pakeistieji enaminokarbonilo junginiai
DK3178792T3 (da) Fremgangsmåde til aflejringshæmning
BRPI0810365A2 (pt) Inibidores de mlc-1 de indol 7-substituído
EP2049520A4 (en) indole compounds
ATE524477T1 (de) Aziridinylepothilonverbindungen
HK1160110A1 (en) Compounds useful for inhibiting chk1
DK2107971T3 (da) Kombineret blækfamilie profilering til en blækpatron
EP2079466A4 (en) SUBSTITUTED INDOLE COMPOUNDS
DE602008001144D1 (de) Kogenerationssystem
BRPI0822916A2 (pt) Combustível sólido
BRPI0720097A2 (pt) Compostos de fosfonato
FI20065446A0 (fi) Muodostusosa
BRPI0720310A2 (pt) Injetor aperfeiçoado de sólidos particulados
ITTO20070893A1 (it) Gruppo motopropulsore per motociclo.
ATE527249T1 (de) Indole
DE502008000044D1 (de) Kraftstoffverteiler
DK2097309T3 (da) Cykelgenerator
DK1862615T3 (da) Nøgle
DK2121421T3 (da) To-dels generator til cykler
ITMN20070006A1 (it) Caldaia per combustibile solido
FI20065196A0 (fi) Muodostusosa
ITRM20080003A1 (it) Miscela inertizzante per rifiuti da zld
ITMI20072333A1 (it) Blocco combustibile solido
FR2910077B1 (fr) Generateur anemo-solaire